Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net ...

Salesforce has announced a new CFO+ with an expanded set of responsibilities as a company veteran who "bleeds CRM" prepares ...

A new rule requires insurers to improve coverage of PrEP, which can prevent HIV, but Georgians face challenges getting the ...

In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Gilead Sciences (GILD – Research Report), with a price ...

(KOA), the largest system of privately owned campgrounds in the world, is proud to announce that Mt. Gilead KOA Holiday has ...

Five years ago, Gilead signed a massive deal with Galapagos. After a restructuring, the pharma is still hunting for the potential it saw at the original signing. Gilead had reached an inflection point ...

Gilead Sciences’ Livdelzi (seladelpar) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat adults with the rare liver disease primary biliary cholangitis (PBC) ...

GS-0272 is under clinical development by Gilead Sciences and currently in Phase I for Rheumatoid Arthritis. According to GlobalData, Phase I drugs for Rheumatoid Arthritis have a 69% phase transition ...

Gilead Sciences Inc. and the federal government settled a patent-infringement case in which the US sought $1 billion from the bioscience giant for allegedly using joint research to develop an ...

After a run of court victories in a five-year patent dispute with the U.S. government, Gilead Sciences has agreed to settle with the Department of Justice (DOJ) and the Department of Health and ...

Brian Heath has joined Gilead Sciences’ cell therapy subsidiary as a senior vice president and head of global commercial, he announced on LinkedIn this week. “CAR T-cell therapy has changed ...